Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday, February 19th.
According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
AUPH has been the topic of several other research reports. BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. Leerink Swann increased their target price on Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 15th. ValuEngine raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Canaccord Genuity set a $11.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, November 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $10.59.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up $0.01 during trading hours on Monday, reaching $5.36. The company’s stock had a trading volume of 373,092 shares, compared to its average volume of 598,382. Aurinia Pharmaceuticals has a 12 month low of $4.41 and a 12 month high of $9.83. The stock has a market cap of $449.26, a PE ratio of -4.43 and a beta of 2.30.
Institutional investors have recently bought and sold shares of the business. Kazazian Asset Management LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 11.6% in the 4th quarter. Kazazian Asset Management LLC now owns 156,126 shares of the biotechnology company’s stock valued at $707,000 after buying an additional 16,189 shares during the period. Goldman Sachs Group Inc. raised its holdings in Aurinia Pharmaceuticals by 36.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,194,550 shares of the biotechnology company’s stock worth $5,411,000 after purchasing an additional 319,639 shares during the last quarter. Franklin Resources Inc. raised its holdings in Aurinia Pharmaceuticals by 33.2% during the fourth quarter. Franklin Resources Inc. now owns 1,664,400 shares of the biotechnology company’s stock worth $7,540,000 after purchasing an additional 414,400 shares during the last quarter. Hudson Bay Capital Management LP raised its holdings in Aurinia Pharmaceuticals by 20.0% during the fourth quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock worth $2,039,000 after purchasing an additional 75,000 shares during the last quarter. Finally, Spark Investment Management LLC acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $153,000. 28.50% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2018/03/15/aurinia-pharmaceuticals-auph-upgraded-to-hold-at-zacks-investment-research-2.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.